162 related articles for article (PubMed ID: 35710816)
1. Tacrolimus dose adjustment is not necessary in dose to dose conversion from a twice daily to a prolonged release once daily dose form.
Tiankanon K; Kerr SJ; Thongthip S; Udomkarnjananun S; Sodsai P; Vorasittha A; Panumatrassamee K; Takkavatakarn K; Tungsanga K; Eiam-Ong S; Praditpornsilpa K; Avihingsanon Y; Townamchai N
Sci Rep; 2022 Jun; 12(1):10051. PubMed ID: 35710816
[TBL] [Abstract][Full Text] [Related]
2. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
[TBL] [Abstract][Full Text] [Related]
3. The association between trough blood concentration and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation in de novo kidney transplant recipients.
Sukkha S; Chindavijak B; Nosoongnoen W; Phakdeekitchareon B; Kitiyakara C; Sumethkul V
Drug Metab Pharmacokinet; 2020 Feb; 35(1):139-144. PubMed ID: 31727575
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
[TBL] [Abstract][Full Text] [Related]
5. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation.
Stifft F; Stolk LM; Undre N; van Hooff JP; Christiaans MH
Transplantation; 2014 Apr; 97(7):775-80. PubMed ID: 24686426
[TBL] [Abstract][Full Text] [Related]
6. The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients.
Zaltzman AS; Glick LA; Zaltzman JS; Nash M; Huang M; Prasad GV
Transplant Res; 2016; 5():2. PubMed ID: 26823971
[TBL] [Abstract][Full Text] [Related]
7. Effects of CPY3A5 Genetic Polymorphisms on the Pharmacokinetics of Extendedrelease and Immediate-release Tacrolimus Formulations in Renal Transplant Recipients: A Systematic Review and Meta-analysis.
Xie Q; Xiang Q; Liu Z; Mu G; Zhou S; Zhang Z; Ma L; Cui Y
Curr Drug Metab; 2021; 22(10):758-771. PubMed ID: 34525930
[TBL] [Abstract][Full Text] [Related]
8. Trough level from twice daily to once daily tacrolimus in early conversion kidney transplant recipients: a prospective study.
Sukkha S; Chindavijak B; Montakantikul P; Ingsathit A; Nosoongnoen W; Sumethkul V
Int J Clin Pharm; 2017 Dec; 39(6):1298-1303. PubMed ID: 29101615
[TBL] [Abstract][Full Text] [Related]
9. Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy.
Min SI; Ha J; Kang HG; Ahn S; Park T; Park DD; Kim SM; Hong HJ; Min SK; Ha IS; Kim SJ
Am J Transplant; 2013 Aug; 13(8):2191-7. PubMed ID: 23734831
[TBL] [Abstract][Full Text] [Related]
10. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
Kim SH; Lee SD; Kim YK; Park SJ
Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
[TBL] [Abstract][Full Text] [Related]
11. Trough Level and Tacrolimus Variability of Early Converted Once-Daily Tacrolimus: 1-Year Follow-up Study.
Sukkha S; Suansanae T; Iamrahong P; Wiwattanathum P
Transplant Proc; 2020 Apr; 52(3):775-779. PubMed ID: 32143870
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation.
Méndez A; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Blanco A; Camós S; Pou L; Roman A
Transplantation; 2014 Feb; 97(3):358-62. PubMed ID: 24492423
[TBL] [Abstract][Full Text] [Related]
13. Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients.
Ruangkanchanasetr P; Sanohdontree N; Supaporn T; Sathavarodom N; Satirapoj B
Ann Transplant; 2016 Dec; 21():765-774. PubMed ID: 27980321
[TBL] [Abstract][Full Text] [Related]
14. Effects of conversion from a twice-daily tacrolimus to a once-daily tacrolimus on glucose metabolism in stable kidney transplant recipients.
Uchida J; Iwai T; Kabei K; Machida Y; Kuwabara N; Naganuma T; Kumada N; Nakatani T
Transplant Proc; 2014; 46(2):532-6. PubMed ID: 24656005
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic Profile of Twice- and Once-daily Tacrolimus in Pediatric Kidney Transplant Recipients.
Takahashi Y; Shishido S; Hyodo Y; Yonekura T; Nihei H; Itabashi Y; Muramatsu M; Hamasaki Y; Kawamura T; Aikawa A
Transplant Proc; 2017; 49(1):37-40. PubMed ID: 28104153
[TBL] [Abstract][Full Text] [Related]
16. Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.
Glowacki F; Lionet A; Hammelin JP; Labalette M; Provôt F; Hazzan M; Broly F; Noël C; Cauffiez C
Clin Pharmacokinet; 2011 Jul; 50(7):451-9. PubMed ID: 21528942
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
[TBL] [Abstract][Full Text] [Related]
18. Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure.
Shuker N; Cadogan M; van Gelder T; Roodnat JI; Kho MM; Weimar W; Hesselink DA
Ther Drug Monit; 2015 Apr; 37(2):262-9. PubMed ID: 25265255
[TBL] [Abstract][Full Text] [Related]
19. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
[TBL] [Abstract][Full Text] [Related]
20. Conversion to Once-Daily Tacrolimus Results in Increased p38MAPK Phosphorylation in T Lymphocytes of Kidney Transplant Recipients.
Kannegieter NM; Shuker N; Vafadari R; Weimar W; Hesselink DA; Baan CC
Ther Drug Monit; 2016 Apr; 38(2):280-4. PubMed ID: 26606072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
